ABSTRACT
Purpose: To assess early real-world outcomes with brolucizumab in Canadian patients with neovascular age-related macular degeneration (nAMD) for which they previously received ≥1 anti-vascular endothelial growth factor (anti-VEGF) agent(s). Patients and Methods: This multisite, real-world, retrospective chart review included data from a consecutive sample of 73 patients who received brolucizumab for nAMD after treatment with ≥1 other anti-VEGF agents. The principal reasons for switching to brolucizumab were to extend the treatment interval (51.6% of patients) and to treat persistent macular fluid (34.2%). The primary outcomes were best-corrected visual acuity (BCVA) and the incidence rates of intraocular inflammation (IOI), retinal vasculitis (RV), and retinal vascular occlusion (RVO). Secondary outcomes included central retinal thickness (CRT), injection interval, and presence of intraretinal and subretinal fluid (IRF and SRF). All parameters were measured at baseline until the last treatment visit between April 27, 2020, and August 31, 2021. Results: Over a mean follow-up of 28 weeks, a nonsignificant mean improvement in BCVA was identified (4.3 [standard deviation (SD) 8.3] letters; P=0.057), with 47.9% experiencing a gain of ≥5 letters. IOI was detected in 3 patients (4.1%), one of whom also developed RV and RVO (1.4%), which is consistent with existing brolucizumab data. Significant reductions were observed in mean CRT (-36.6 µm [SD 56.1 µm]; P=0.0002) and presence of any macular fluid (56.1% [SD 5.6%]; P<0.001), IRF (66.6% [SD 6.3%]; P<0.001), and SRF (62.7% [SD 6.3%]; P<0.001). The mean injection interval increased significantly by 2.1 weeks (SD 2.7; P<0.001). Conclusion: In the first real-world Canadian analysis, brolucizumab was associated with improvements in functional outcomes in treatment-experienced patients, consistent with other real-world studies. The incidence of IOI, RV, and RVO were in line with the post hoc safety analysis of HAWK and HARRIER data.
ABSTRACT
PURPOSE: The goal of this study was to determine the changes in surgical techniques and leading indications for corneal transplantations performed in the last decade. The impact of administrative changes of corneal banking in Quebec was also evaluated. METHODS: The records of all corneal transplantations performed between January 2000 and December 2011 in the territory subserved by the Quebec Eye Bank and Héma-Québec (Quebec, Canada) were retrospectively reviewed. RESULTS: A total of 3459 corneal transplantations were performed between 2000 and 2011. The rate of corneal transplantation more than doubled from 234 grafts per year in 2000 to 592 grafts per year in 2011. Imported tissue represented 40% of grafted corneas. Increases in tissue importation were seen in 2003 and 2009 to address local tissue shortage and peaks in wait time. The average wait time decreased from 434 ± 456 days (2000-2008) to 418 ± 551 days (2009-2011) (P = 0.01). The leading surgical indications were Fuchs endothelial corneal dystrophy (27%), pseudophakic corneal edema (26%), keratoconus (13%), and viral keratitis (8%). Regrafts represented 25% of procedures. Descemet stripping automated endothelial keratoplasty became the preferred technique for endothelial diseases, surpassing penetrating keratoplasty in 2011. CONCLUSIONS: The surgical indications and techniques used for corneal transplantation in Quebec reflected those of the literature. However, long wait times and corneal tissue shortages mandated significant changes in the organization of the Quebec Eye Bank. Partnering with a larger agency responsible for tissue and blood donation coordination (Héma-Québec) had a positive impact on yearly transplantation rates and wait times.
